Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta-analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta-analysis of the literature published from inception to Dec 31, 2016 was conducted. Case-control studies with vitiligo patients and a control group were included. The prevalence of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti-gastric parietal cell antibodies (AGPCA), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA), and anti-adrenal antibodies in vitiligo patients were 15.1%, 9.7%, 12.5%, 11.7%, 12.6%, 0.2%, and 2.5%, respectively. The prevalence of ATPO antibodies (odds ratio [OR]: 3.975; 95%; confidence interval [CI]: 3.085–5.122), ATG antibodies (OR: 3.759; 95% CI: 2.554–5.531), ANA (OR: 1.797, 95% CI: 1.182–2.731), AGPCA (OR: 2.503; 95% CI: 1.497–2.896), and anti-adrenal antibodies (OR: 9.808, 95% CI: 1.809–53.159) (Figure 2a–e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.
|Translated title of the contribution||Vitiligo and autoantibodies: A systematic review and meta-analysis|
|Number of pages||9|
|Journal||JDDG - Journal of the German Society of Dermatology|
|Publication status||Published - Jul 2018|
ASJC Scopus subject areas